Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. 1999

T Stankovic, and P Weber, and G Stewart, and T Bedenham, and J Murray, and P J Byrd, and P A Moss, and A M Taylor
CRC Institute for Cancer Studies, Medical School, University of Birmingham, Edgbaston, UK.

BACKGROUND Patients with the inherited disorder ataxia telangiectasia (A-T) have an increased susceptibility to lymphoid malignancies. In these patients mutations affect both alleles of the A-T gene (ATM). We have looked for mutations in the ATM gene in sporadic cases of B-cell chronic lymphocytic leukaemia (B-CLL). METHODS 32 cases of B-CLL were analysed by restriction endonuclease fingerprinting to detect mutations within ATM. In six of the cases in which mutations were detected in tumour samples, germline DNA was screened to assess ATM carrier status. The samples in 20 cases were also studied by western blot for abnormal expression of ATM protein. RESULTS Expression of the ATM protein was impaired in eight (40%) of the 20 tumours analysed, being absent in three and decreased in five. Mutations within ATM were detected in six (18%) of the 32 patients. These point mutations, deletions, and one insertion were distributed across the coding sequence of ATM. Germline mutations, which indicate ATM carrier status, were found in two of these six patients compared with a frequency within the general population of below 1 in 200. CONCLUSIONS Abnormal expression of ATM protein is a frequent finding in B-CLL. Although the precise function of this protein is unknown, it is thought to have a role in programmed cell death, a deficiency of which would fit with the characteristic phenotype of prolonged cell survival seen in B-CLL tumour cells. Our results also suggest that carriers of ATM mutations may be at a particular risk for the development of B-CLL and this may partly explain the known genetic susceptibility to this disease.

UI MeSH Term Description Entries
D008297 Male Males
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D002880 Chromosomes, Human, Pair 11 A specific pair of GROUP C CHROMOSOMES of the human chromosome classification. Chromosome 11
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004262 DNA Restriction Enzymes Enzymes that are part of the restriction-modification systems. They catalyze the endonucleolytic cleavage of DNA sequences which lack the species-specific methylation pattern in the host cell's DNA. Cleavage yields random or specific double-stranded fragments with terminal 5'-phosphates. The function of restriction enzymes is to destroy any foreign DNA that invades the host cell. Most have been studied in bacterial systems, but a few have been found in eukaryotic organisms. They are also used as tools for the systematic dissection and mapping of chromosomes, in the determination of base sequences of DNAs, and have made it possible to splice and recombine genes from one organism into the genome of another. EC 3.21.1. Restriction Endonucleases,DNA Restriction Enzyme,Restriction Endonuclease,Endonuclease, Restriction,Endonucleases, Restriction,Enzymes, DNA Restriction,Restriction Enzyme, DNA,Restriction Enzymes, DNA
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005260 Female Females
D006579 Heterozygote An individual having different alleles at one or more loci regarding a specific character. Carriers, Genetic,Genetic Carriers,Carrier, Genetic,Genetic Carrier,Heterozygotes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

T Stankovic, and P Weber, and G Stewart, and T Bedenham, and J Murray, and P J Byrd, and P A Moss, and A M Taylor
February 1999, Lancet (London, England),
T Stankovic, and P Weber, and G Stewart, and T Bedenham, and J Murray, and P J Byrd, and P A Moss, and A M Taylor
April 1986, International journal of cancer,
T Stankovic, and P Weber, and G Stewart, and T Bedenham, and J Murray, and P J Byrd, and P A Moss, and A M Taylor
October 2017, Journal of virology,
T Stankovic, and P Weber, and G Stewart, and T Bedenham, and J Murray, and P J Byrd, and P A Moss, and A M Taylor
August 2015, Haematologica,
T Stankovic, and P Weber, and G Stewart, and T Bedenham, and J Murray, and P J Byrd, and P A Moss, and A M Taylor
December 2012, Journal of virology,
T Stankovic, and P Weber, and G Stewart, and T Bedenham, and J Murray, and P J Byrd, and P A Moss, and A M Taylor
August 1994, British journal of haematology,
T Stankovic, and P Weber, and G Stewart, and T Bedenham, and J Murray, and P J Byrd, and P A Moss, and A M Taylor
January 2010, Sheng wu gong cheng xue bao = Chinese journal of biotechnology,
T Stankovic, and P Weber, and G Stewart, and T Bedenham, and J Murray, and P J Byrd, and P A Moss, and A M Taylor
July 2001, Journal of clinical pathology,
T Stankovic, and P Weber, and G Stewart, and T Bedenham, and J Murray, and P J Byrd, and P A Moss, and A M Taylor
January 2002, Blood,
T Stankovic, and P Weber, and G Stewart, and T Bedenham, and J Murray, and P J Byrd, and P A Moss, and A M Taylor
November 1981, British journal of haematology,
Copied contents to your clipboard!